Solid biosciences to participate at guggenheim healthcare talks: genomic medicines and rare disease day

Cambridge, mass., march 25, 2021 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy (duchenne), today announced that carl morris, ph.d., chief scientific officer, will participate in a panel discussion at the virtual guggenheim healthcare talks: genomic medicines and rare disease day. the panel entitled “the more we learn the less we know about dmd—from micro-dystrophin, to morpholinos, and small molecules” will be held on thursday, april 1, 2021 from 9:00 a.m. - 9:50 a.m. eastern time.
SLDB Ratings Summary
SLDB Quant Ranking